HRP20210517T1 - Pripravci i postupci za protutijela usmjerena na epo - Google Patents

Pripravci i postupci za protutijela usmjerena na epo Download PDF

Info

Publication number
HRP20210517T1
HRP20210517T1 HRP20210517TT HRP20210517T HRP20210517T1 HR P20210517 T1 HRP20210517 T1 HR P20210517T1 HR P20210517T T HRP20210517T T HR P20210517TT HR P20210517 T HRP20210517 T HR P20210517T HR P20210517 T1 HRP20210517 T1 HR P20210517T1
Authority
HR
Croatia
Prior art keywords
sequence
seq
nucleic acid
acid molecule
antigen
Prior art date
Application number
HRP20210517TT
Other languages
English (en)
Inventor
Joy GHOSH
Mark Anthony RUTZ
Katrin Ulrike TISSOT-DAGUETTE
Igor Splawski
Michael Roguska
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49881001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210517(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20210517T1 publication Critical patent/HRP20210517T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (18)

1. Izolirano protutijelo ili njegov ulomak koji veže antigen koji veže ljudski eritropoetin (Epo), naznačeno time, da sadrži sekvence varijabilne domene teškog i lakog lanca Fab NVS1 predstavljene sa SEQ ID NO: 13 i 14, istim redom; od Fab NVS2 predstavljene sa SEQ ID NO: 33 i 34, istim redom; od Fab NVS3 predstavljene sa SEQ ID NO: 53 i 54, istim redom; ili od Fab NVS4 predstavljene sa SEQ ID NO: 73 i 74, istim redom.
2. Izolirano protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1, naznačeno time, da protutijelo ili njegov ulomak koji veže antigen sadrži sekvence varijabilne domene teškog i lakog lanca Fab NVS2 predstavljene sa SEQ ID NO: 33 i 34, istim redom.
3. Izolirano protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 1, naznačeno time, da protutijelo ili njegov ulomak koji veže antigen sadrži sekvence teškog i lakog lanca SEQ ID NO: 15 i 16, istim redom; SEQ ID NO: 35 i 36, istim redom; SEQ ID NO: 55 i 56, istim redom; ili SEQ ID NO: 75 i 76, istim redom.
4. Izolirano protutijelo ili njegov ulomak koji veže antigen prema patentnom zahtjevu 3, naznačeno time, da protutijelo ili njegov ulomak koji veže antigen sadrži sekvence teškog i lakog lanca SEQ ID NO: 35 i 36, istim redom.
5. Izolirana molekula nukleinske kiseline, naznačena time, da sadrži nukleotidnu sekvencu koja kodira protutijelo ili ulomak koji kodira antigen prema bilo kojem od prethodnih patentnih zahtjeva.
6. Molekula nukleinske kiseline prema patentnom zahtjevu 5, naznačena time, da navedena molekula nukleinske kiseline sadrži sekvencu koja kodira varijabilnu domenu teškog lanca i navedena sekvenca je najmanje 95% identična u odnosu na sekvencu sa sekvencom odabranom od SEQ ID NO: 17, 37, 57 i 77.
7. Molekula nukleinske kiseline prema patentnom zahtjevu 5, naznačena time, da navedena molekula nukleinske kiseline sadrži sekvencu koja kodira varijabilnu domenu teškog lanca i navedena sekvenca je najmanje 95% identična u odnosu na sekvencu sa sekvencom SEQ ID NO: 37.
8. Molekula nukleinske kiseline prema patentnom zahtjevu 5, naznačena time, da navedena molekula nukleinske kiseline sadrži sekvencu koja kodira teški lanac i navedena sekvenca je najmanje 95% identična u odnosu sa sekvencu sa sekvencom SEQ ID NO: 39.
9. Molekula nukleinske kiseline prema patentnom zahtjevu 5, naznačena time, da navedena molekula nukleinske kiseline sadrži sekvencu koja kodira varijabilnu domenu lakog lanca i navedena sekvenca je najmanje 95% identična u odnosu na sekvencu sa sekvencom odabranom od SEQ ID NO: 18, 38, 58 i 78.
10. Molekula nukleinske kiseline prema patentnom zahtjevu 5, naznačena time, da navedena molekula nukleinske kiseline sadrži sekvencu koja kodira varijabilnu domenu lakog lanca i navedena sekvenca je najmanje 95% identična u odnosu na sekvencu sa sekvencom SEQ ID NO: 38.
11. Molekula nukleinske kiseline prema patentnom zahtjevu 5, naznačena time, da navedena molekula nukleinske kiseline sadrži sekvencu koja kodira laki lanac i navedena sekvenca je najmanje 95% identična u odnosu na sekvencu sa sekvencom SEQ ID NO: 40.
12. Vektor, naznačen time, da sadrži molekulu nukleinske kiseline prema bilo kojem od patentnih zahtjeva 5 do 11.
13. Izolirana stanica domaćina, naznačena time, da sadrži nukleinsku kiselinu prema bilo kojem od patentnih zahtjeva 5 do 11 ili vektor prema patentnom zahtjevu 12.
14. Pripravak, naznačen time, da sadrži protutijelo ili ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 4, i farmaceutski prihvatljivo sredstvo za razrjeđivanje ili nosač.
15. Pripravak koji sadrži protutijelo ili njegov ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da je za uporabu u inhibiciji EPO-ovisne stanične proliferacije kod pojedinca.
16. Pripravak koji sadrži protutijelo ili njegov ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da je za uporabu u liječenju vaskularne bolesti mrežnice kod pojedinca.
17. Pripravak za uporabu prema patentnom zahtjevu 16, naznačen time, da je vaskularna bolest mrežnice kod pojedinca povezana s bolešću ili stanjem odabranim od: dijabetičke retinopatije, dijabetičkog makularnog edema, proliferativne dijabetičke retinopatije, ne-proliferativne dijabetičke retinopatije, starosne makularne degeneracije, okluzije središnje mrežnične vene, multifokalnog horoiditisa, miopijske horoidalne neovaskularizacije i retinopatije nedonoščadi.
18. Pripravak koji sadrži protutijelo ili njegov ulomak koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da je za uporabu u liječenju makularnog edema.
HRP20210517TT 2012-12-05 2021-03-30 Pripravci i postupci za protutijela usmjerena na epo HRP20210517T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261733566P 2012-12-05 2012-12-05
EP13812296.5A EP2928921B1 (en) 2012-12-05 2013-12-03 Compositions and methods for antibodies targeting epo
PCT/US2013/072915 WO2014089111A1 (en) 2012-12-05 2013-12-03 Compositions and methods for antibodies targeting epo

Publications (1)

Publication Number Publication Date
HRP20210517T1 true HRP20210517T1 (hr) 2021-05-14

Family

ID=49881001

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210517TT HRP20210517T1 (hr) 2012-12-05 2021-03-30 Pripravci i postupci za protutijela usmjerena na epo

Country Status (29)

Country Link
US (5) US9365646B2 (hr)
EP (2) EP3851454A1 (hr)
JP (5) JP6306605B2 (hr)
KR (2) KR102233664B1 (hr)
CN (2) CN104968678B (hr)
AP (1) AP2015008365A0 (hr)
AR (1) AR093803A1 (hr)
AU (4) AU2013355414B2 (hr)
CA (1) CA2893767C (hr)
CL (1) CL2015001472A1 (hr)
CY (1) CY1124028T1 (hr)
DK (1) DK2928921T3 (hr)
EA (1) EA033643B1 (hr)
ES (1) ES2864326T3 (hr)
HR (1) HRP20210517T1 (hr)
HU (1) HUE053669T2 (hr)
LT (1) LT2928921T (hr)
MX (1) MX368067B (hr)
PH (1) PH12015501243B1 (hr)
PL (1) PL2928921T3 (hr)
PT (1) PT2928921T (hr)
RS (1) RS61648B1 (hr)
SG (1) SG11201503567SA (hr)
SI (1) SI2928921T1 (hr)
TN (1) TN2015000124A1 (hr)
TW (1) TW201434858A (hr)
UY (1) UY35168A (hr)
WO (1) WO2014089111A1 (hr)
ZA (2) ZA201502291B (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368067B (es) * 2012-12-05 2019-09-18 Novartis Ag Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN104877971B (zh) * 2015-06-02 2018-03-30 汉恒生物科技（上海）有限公司 一种可以缓解小鼠心衰症状的携带mg53基因的腺相关病毒载体
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
US20190023806A1 (en) * 2015-10-21 2019-01-24 Qoolabs, Inc. Camelid hemoglobin antibodies and methods of use
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
RS61412B1 (sr) * 2016-03-17 2021-03-31 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR101965814B1 (ko) 2017-02-27 2019-08-13 재단법인 대구경북과학기술원 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용
KR102167641B1 (ko) 2018-08-27 2020-10-19 주식회사 사이루스 에리스로포이에틴 유래 펩티드를 함유하는 세포증식 촉진용 조성물
CN113194998A (zh) * 2018-10-10 2021-07-30 约翰霍普金斯大学 用于非病毒递送用于基因编辑和视网膜基因治疗的质粒DNA的聚(β-氨基酯)纳米颗粒
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
WO2023280391A1 (en) * 2021-07-06 2023-01-12 Andremacon S.R.L. Anti-erythropoietin antibody
JP7452516B2 (ja) 2021-10-28 2024-03-19 トヨタ自動車株式会社 注意能力検査装置、および、車両

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
DE3924746A1 (de) 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
MX9700764A (es) 1994-07-29 1997-05-31 Smithkline Beecham Plc Compuestos novedosos.
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU6909298A (en) 1996-10-28 1998-05-22 Novartis Ag Method for the oligomerisation of peptides
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
DK1642910T3 (da) 2000-12-05 2012-05-07 Alexion Pharma Inc Rationelt designede atistoffer
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003304034A1 (en) 2002-08-09 2004-11-01 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
AU2003303144A1 (en) 2002-10-18 2004-07-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20050255112A1 (en) 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
PT1772465E (pt) 2005-01-05 2009-05-21 F Star Biotech Forsch & Entw Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
AU2006316450A1 (en) 2005-11-24 2007-05-31 Merck Serono Sa Erythropoietin polypeptides and uses thereof
AR060440A1 (es) 2006-04-14 2008-06-18 Amgen Inc Agonistas receptores de eritropoietina
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
WO2008079877A2 (en) 2006-12-22 2008-07-03 Xenon Pharmaceuticals Inc. Compositions and methods for the diagnosis and treatment of iron-related disorders
WO2008112703A2 (en) 2007-03-12 2008-09-18 University Of Utah Research Foundation Compositions and methods for diagnosing and treating diabetic micro vascular complications
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
JP5815403B2 (ja) * 2008-08-05 2015-11-17 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
CN102131829A (zh) 2008-08-28 2011-07-20 弗·哈夫曼-拉罗切有限公司 抗人epo受体抗体
WO2010054010A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
WO2010056893A1 (en) 2008-11-13 2010-05-20 Imclone Llc Humanization and affinity-optimization of antibodies
CA3018087C (en) 2009-01-15 2019-09-24 F. Hoffmann-La Roche Ag Antibodies against phosphorylated tyrosines on erythropoietin receptor (epor)
CN102666875A (zh) 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
EP2625203A1 (en) * 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20120207743A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
US8623666B2 (en) 2011-06-15 2014-01-07 Hoffmann-La Roche Inc. Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US9441039B2 (en) * 2012-05-07 2016-09-13 Amgen Inc. Anti-erythropoietin antibodies
EP2890836B1 (en) 2012-08-31 2019-07-17 The Scripps Research Institute Methods related to modulators of eukaryotic cells
MX368067B (es) 2012-12-05 2019-09-18 Novartis Ag Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).

Also Published As

Publication number Publication date
CL2015001472A1 (es) 2015-12-04
US10106605B2 (en) 2018-10-23
CA2893767A1 (en) 2014-06-12
SI2928921T1 (sl) 2021-05-31
US9365646B2 (en) 2016-06-14
EP2928921B1 (en) 2021-01-20
US20160280783A1 (en) 2016-09-29
KR20150090101A (ko) 2015-08-05
EP3851454A1 (en) 2021-07-21
KR102386154B1 (ko) 2022-04-12
PH12015501243A1 (en) 2015-08-17
AU2018253639B2 (en) 2020-12-10
AU2021201487B2 (en) 2023-02-02
JP7250852B2 (ja) 2023-04-03
US10385127B2 (en) 2019-08-20
AU2017202898A1 (en) 2017-05-25
ZA201602366B (en) 2021-08-25
AU2018253639A1 (en) 2018-11-22
CA2893767C (en) 2022-11-08
EA201591010A1 (ru) 2015-10-30
US20210355206A1 (en) 2021-11-18
JP2021176850A (ja) 2021-11-11
CN104968678A (zh) 2015-10-07
AP2015008365A0 (en) 2015-04-30
ES2864326T3 (es) 2021-10-13
JP2016501890A (ja) 2016-01-21
EA033643B1 (ru) 2019-11-12
WO2014089111A1 (en) 2014-06-12
TN2015000124A1 (en) 2016-10-03
AU2021201487A1 (en) 2021-03-25
AU2013355414A1 (en) 2015-04-23
JP6937858B2 (ja) 2021-09-22
US20190135913A1 (en) 2019-05-09
US20200048341A1 (en) 2020-02-13
CY1124028T1 (el) 2022-05-27
AU2017202898B2 (en) 2018-08-09
RS61648B1 (sr) 2021-04-29
AR093803A1 (es) 2015-06-24
CN109517063A (zh) 2019-03-26
DK2928921T3 (da) 2021-04-19
KR102233664B1 (ko) 2021-04-02
ZA201502291B (en) 2021-02-24
LT2928921T (lt) 2021-04-26
EP2928921A1 (en) 2015-10-14
BR112015011363A2 (pt) 2017-08-22
PT2928921T (pt) 2021-04-06
CN104968678B (zh) 2018-12-11
JP2020114218A (ja) 2020-07-30
SG11201503567SA (en) 2015-06-29
UY35168A (es) 2014-07-31
AU2018253639B9 (en) 2020-12-24
KR20210035921A (ko) 2021-04-01
CN109517063B (zh) 2022-07-01
JP2023029993A (ja) 2023-03-07
TW201434858A (zh) 2014-09-16
AU2013355414B2 (en) 2017-02-02
MX2015007191A (es) 2015-10-14
US20140199306A1 (en) 2014-07-17
PH12015501243B1 (en) 2015-08-17
HUE053669T2 (hu) 2021-07-28
PL2928921T3 (pl) 2021-06-28
JP6306605B2 (ja) 2018-04-04
MX368067B (es) 2019-09-18
JP2018113974A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
HRP20210517T1 (hr) Pripravci i postupci za protutijela usmjerena na epo
HRP20201505T1 (hr) Široko neutralizirajuća anti-hiv protutijela
MX2014001019A (es) Dominios variables singulares anti-vgf fusionados con dominios de fc.
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
HRP20210393T1 (hr) Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja
HRP20201852T1 (hr) Optimizacija antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene
NZ741780A (en) Anti-htra1 antibodies and methods of use thereof
CN107406508A (zh) 人源化的抗trop‑2单克隆抗体及其应用
HRP20211453T1 (hr) Liječenje amd uporabom aav sflt-1
CY1123697T1 (el) Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη
HRP20140244T1 (hr) Sastavi i metode za inhibiranje pdgfrbeta i vegf-a
JP2015501814A5 (hr)
PE20170071A1 (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas
JP2016504416A5 (hr)
JP2018500014A5 (hr)
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
PH12015501352A1 (en) Compositions and methods that utilize a peptide tag that binds to hyaluronan
RU2017102514A (ru) Гуманизированные анти-тау-антитела
HRP20150281T1 (hr) Prevencija i lijeäśenje stanja oka povezanih sa sustavom komplementa
HRP20191945T1 (hr) Poboljšana il-6-protutijela
KR20160113272A (ko) Tim-3에 대한 항체 분자 및 그의 용도
RU2015144105A (ru) Антитела к гепсидину и их применения
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
AR076796A1 (es) Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento.
PE20211767A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g